As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma’s road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP: